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Abstract   32	
 33	
Purpose of Review 34	
In addition to being essential for movement, skeletal muscles act as both a store and 35	
source of key macronutrients. As such, muscle is an important tissue for whole body 36	
homeostasis, undergoing muscle wasting in times of starvation, disease and stress 37	
e.g. to provide energy substrates for other tissues. Yet, muscle wasting is also 38	
associated with disability, co-morbidities and mortality. Since nutrition is so crucial to 39	
maintaining muscle homeostasis “in health”, it has been postulated that muscle 40	
wasting in cachexia-syndromes may be alleviated by nutritional interventions. This 41	
review will highlight recent work in this area in relation to muscle kinetics, the acute 42	
metabolic (e.g. dietary protein), and longer-term effects of dietary interventions.  43	
 44	
Recent Findings 45	
Whole-body and skeletal muscle protein synthesis invariably exhibit deranged 46	
kinetics (favoring catabolism) in wasting states; further, many of these conditions 47	
harbor blunted anabolic responses to protein-nutrition compared to healthy controls. 48	
These derangements underlie muscle wasting. Recent trials of essential amino acid 49	
(EAA) and protein-based nutrition have shown some potential for therapeutic benefit. 50	
   51	
Summary 52	
Nutritional modulation, particularly of dietary-AA, may have benefits to prevent or 53	
attenuate disease-induced muscle wasting. Nonetheless, there remains a lack of 54	
recent studies exploring these key concepts to make conclusive recommendations.  55	
 56	
200 words 57	
 58	
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 59	
Introduction 60	
	 	61	
Skeletal muscle facilitates locomotion and is metabolically important in 62	
providing a large capacity for glucose and intramuscular lipid storage for 63	
energy production, as well as the body’s largest reservoir of amino acids (AA) 64	
[1]. Clinically this makes muscle a vital support mechanism in times of need 65	
e.g. i) releasing AA for tissue repair in response to diseases, trauma and 66	
starvation, and ii) compensating for failing organs (i.e liver and kidneys). Both 67	
communicable infectious and non-communicable diseases are associated 68	
with skeletal muscle wasting; collectively known as “cachexia” syndromes 69	
these include: cancers [2], metabolic diseases such as diabetes [3], auto-70	
immune/immune-deficiency diseases such as rheumatoid arthritis [4] in 71	
addition to organ failures, e.g. cirrhosis [5], chronic obstructive pulmonary 72	
disease (COPD) [6] congestive heart failure (CHF) [7]. Cachexia is defined as 73	
an involuntary and progressive weight loss primarily due to muscle wasting 74	
with or without associated loss of fat mass [8]. The mechanisms underlying 75	
muscle wasting include disease-led catabolism, co-morbidities, poly-76	
pharmacy, physical inactivity and malnutrition [9]. Crucially, muscle wasting 77	
has been shown to be clinically important as it is a strong predictor of mortality 78	
in many clinical conditions [10]. Nonetheless, interventions to mitigate 79	
cachexia are limited, since pharmaceutical treatments to increase muscle 80	
mass are yet to show efficacy [11]. This has led to the search for nutritional 81	
support strategies. 82	
  83	
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Skeletal muscle mass is under tight homeostatic regulation with a 84	
precise diurnal balance being maintained between muscle protein synthesis 85	
(MPS) and muscle protein breakdown (MPB). This equilibrium is dynamic 86	
across fasted-fed cycles. The intake of food enhances MPS and suppresses 87	
MPB via EAA-mediated stimulation of MPS [12] and insulin mediated 88	
suppression of MPB [13]. Yet, a key feature of cachexia is that it cannot be 89	
completely reversed with conventional nutritional support [9], suggesting a 90	
disturbance in these key homeostatic/proteostatic processes.	Ultimately, this 91	
results in muscle wasting that standard nutritional provision cannot restore - 92	
hence, the search for nutritional/nutraceutical strategies.	 This timely review 93	
will summarise new knowledge into the metabolic basis of muscle wasting in 94	
diseases (note: where sufficient recent data exists), and associated nutrient 95	
therapies that have been trialed – all with a strict focus on clinical studies. 96	
 97	
What’s new in cancer nutritional management? 98	
 99	
Cachexia is prevalent in nearly half of all cancer patients exhibiting ~10% 100	
body-weight loss, and accounts for ~20-25% of all cancer deaths [14]. In 101	
addition to inactivity and malnutrition, cachexia is driven by disease processes 102	
(e.g. inflammation [8]) and disease-modifying treatments e.g. chemotherapy 103	
[15]. Insights into the regulation of cancer cachexia have been achieved using 104	
protein kinetic measurements. For instance, it was recently shown that 105	
pancreatic cancer patients (weight loss >10%) exhibited increased whole 106	
body protein synthesis (WBPS) and whole body protein breakdown (WBPB) 107	
compared to controls in the fasted state, resulting in no difference in net 108	
balance (NB) [16]. In contrast, in non-cachectic advanced non-small cell lung 109	
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cancer (NSCLC) patients (stage III/IV unresectable), no differences in WBPS 110	
or WBPB were observed, yet overall, NSCLC displayed decreased NB [17]. 111	
Other studies have focused on how the feeding response is affected by 112	
cancer burden; one such study illustrated that sip-feeding over 4h (24g 113	
casein/86.4g carbohydrate/31.2g fat) had no effect on WBPS in pancreatic 114	
cancer patients. Nonetheless, similar improvements in NB were achieved 115	
compared to healthy controls through suppressed WBPB [16]. Conversely, 116	
14g of leucine-enriched (40%) EAA increased WBPS and NB equally between 117	
NSCLC patients vs. healthy controls [17], similar to what was previously 118	
shown in NSCLC patients in response to hyperaminoacidemia [2]. Disparities 119	
in fasted and fed-state results between van Dijk et al. [16] and Engelen et al. 120	
[17] could be due to different type of cancers (pancreatic vs. NSCLC), with 121	
pancreatic cancer patients exhibiting greater cachexia as shown by van Dijk 122	
et al. (>10% vs. 0 in Engelen). That being said, both groups displayed 123	
elevated C-reactive protein (CRP) (8.3mg/ml and 9.8mg/ml respectively), 124	
while CRP positively correlated with MPB only in van Dijk et al. [16]. Overall 125	
these studies indicate high levels of EAA may provide benefits for increasing 126	
WBPS and NB in cancer patients. Yet the effectiveness at increasing muscle 127	
protein synthesis is difficult to interpret as measures of whole body protein 128	
kinetics include that of all organs that may also display altered protein 129	
metabolism. 130	
Additional work has been performed looking at MPS via gold-standard 131	
direct incorporation methods. In cachectic colorectal cancer patients, fasted-132	
state MPS was unchanged compared to controls, although leg MPB tended to 133	
be increased [18]. Moreover, in response to AA infusions over 2.5h 134	
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(102mg/kg/h), blunted increases in MPS were evident in cancer patients 135	
compared to controls [18]. In contrast to these results, a population of mixed 136	
advanced non-cachectic cancer patients showed increased MPS in response 137	
to a formulated medical food high in protein and free-leucine compared to a 138	
control medical food (40g vs. 24g protein, 4.16g vs. 0g free leucine 139	
respectively). Nonetheless, in the absence of a healthy control group 140	
comparison, whether this was an “overcoming of anabolic resistance” or 141	
simply a dose response phenomenon cannot be determined. Recently, 142	
cumulative MPS was measured using D2O in upper gastrointestinal patients 143	
over 7-days. Intriguingly, MPS was the same as controls and was further 144	
increased in weight losing patients [19]; these results could be driven by 145	
elevated MPS, matched with an equal or greater increase in MPB (not 146	
measured). Further, activity and diet were not monitored, that will affect 147	
cumulative MPS [19–21].  148	
Together these protein kinetic studies demonstrate that cancer may 149	
alter whole body protein kinetics, perhaps to an extent dependent upon 150	
cancer type and progression of cachexia. Further, protein synthesis (particular 151	
that of muscle) may in some instances exhibit anabolic resistance to protein 152	
feeding. This is confirmed by the fact that, 6-weeks after tumor resection, 153	
Williams et al. demonstrated the restoration of anabolic sensitivity in these 154	
patients [18]. That said, providing EAA enriched protein sources may provide 155	
benefits in overcoming anabolic insensitivity in muscle [17,22] – yet whether it 156	
can truly restore MPS to the same as controls remains to be confirmed. It is 157	
patently clear that larger are more tightly controlled studies are needed. 158	
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Recent guidelines on nutrition in cancer suggest that malnutrition 159	
should be taken into consideration and avoided by providing/advising on 160	
adequate nutritional intake. While optimal protein intake has not been 161	
determined in cancer patients, a minimum of 1g/kg/day is suggested with a 162	
target of 1.2-2g/kg/d [23]. Recently, colorectal cancer patients with weight loss 163	
>1kg in the past 3-6 months received pre-operative oral supplementation of 164	
24g protein/d (5-15 days), although this did not prevent further losses in fat 165	
free mass index (FFMI) -0.345 kg.m2 [24]. In another trial, newly diagnosed 166	
oesophageal cancer patients were randomized to receive placebo or a 167	
specially formulated medical food similar to that previously described [22]. 168	
Patients consumed 2x200ml; consisting of 9.9 g protein, 1.1 g free leucine, 169	
0.6 g eicosapentaenoic acid (EPA), 0.3 g docosahexaenoic acid (DHA) and a 170	
balanced mix of vitamins, minerals, and trace elements per 100ml for 4-171	
weeks. After supplementation, the specially formulated medical food resulted 172	
in a significant increase in body weight (approximately 1.25kg) and functional 173	
performance [25].  Energy dense high protein oral nutritional supplementation 174	
or parental nutrition have shown efficacy at increasing weight, although this is 175	
not always the case [26]. With cachectic patients having greater protein 176	
needs, increased provision is likely to be beneficial. Variability between 177	
studies is introduced by diverse individual cancer phenotypes rendering 178	
interpretations difficult.   179	
Further to protein, there are other nutraceutical interventions that may 180	
herald benefits for increasing body weight in cancer. The primary anabolic 181	
effects of protein arise from the EAA and leucine content, along with the 182	
metabolite β-hydroxy-β-methylbutyrate (HMB). Nonetheless, supplementing 183	
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mixtures of HMB/arginine/glutamine in muscle wasting conditions has shown 184	
both increases, or no effect on body weight [27,28]. Fish oil derived fatty 185	
acids, particularly N-3 fatty acids, have many health benefits in both health 186	
and disease. A recent review investigating the effect of purified EPA, or EPA 187	
and DHA combined on body composition in cancer highlights studies 188	
reporting an increase or stabilization of lean body mass and weight, along 189	
with decreasing inflammation [23,29]. Nutritional support to increase energy 190	
and protein intake, through nutritional counselling or supplementation is 191	
recommended in cancer patients [23]. However, there is currently a lack of 192	
strong consistent evidence that long term supplementation of e.g. protein, AA 193	
(or metabolites of), or long chain N-3 fatty acids robustly improve lean mass 194	
[23,28]. Nonetheless, there are multiple studies reporting increases in weight 195	
when utilizing high EAA and high EPA interventions. Combined with the 196	
promising results of EAA/protein on whole body and MPS, oral nutritional 197	
support (ONS) strategies may hold clinical benefits in cancer patients [26]. 198	
 199	
What’s new in immune and metabolic disease nutritional management? 200	
 201	
Rheumatoid arthritis is an idiopathic autoimmune disease affecting synovial 202	
joints. A complex network of chemokines and cytokines (particular TNFa and 203	
IL-6) promote an inflammatory response that attracts immune cells to the 204	
synovial fluid- stimulating osteoclast regeneration, bone and cartilage 205	
degradation by matrix metalloproteinase and a perpetuation of inflammation 206	
[30]. RA is commonly accompanied by muscle wasting of poorly defined 207	
etiology, although chronic inflammation has been suggested to contribute [4]. 208	
Muscle protein kinetics have recently been investigated in non-cachectic RA 209	
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patients. In the fasted state there was no difference between MPS and MPB 210	
in RA patients vs. healthy age-matched controls [31]. Moreover, in response 211	
to whey protein (0.5g/kg/LBM) there was an equal increase in MPS and 212	
suppression in MPB. This group of individuals were described to be ‘well 213	
functioning’ and did not display reductions in muscle strength or mass. Further 214	
these patients were receiving disease modifying antirheumatic drug 215	
(DMARD), methotrexate and although exhibiting inflammation (TNFa, IL6, 216	
CRP) this was less than previous studies [31]. Overall this suggests anabolic 217	
resistance is not present in RA, although there are no studies to make 218	
comparisons to, and this may be different where overt cachexia is present. 219	
 Generally RA patients exhibit energy and protein requirements similar 220	
to age-matched controls [4]. Nevertheless, it was shown that mixtures of non-221	
EAA (alanine, glutamic acid, glycine, and serine) vs. HMB, glutamine and 222	
arginine supplements were equally effective at increasing muscle mass in RA 223	
patients [4,32]. However, recent studies into the effects of nutritional 224	
supplementation on lean mass in RA patients are lacking. Interestingly 12-225	
weeks of creatine supplementation was shown to increase lean mass in RA 226	
patients [33] potentially offering an effective way to restore muscle mass. 227	
Furthermore, with the preserved anabolic sensitivity, increased protein 228	
supplementation may help prevent or restore muscle mass losses, although 229	
again, larger and more controlled and detailed studies are needed.  230	
 Type I Diabetes (T1DM) is an auto-immune condition resulting in a lack 231	
of insulin production due to destruction of pancreatic beta cells and has a 232	
major negative impact on skeletal muscle [34]. A primary action of insulin on 233	
human muscle is the suppression of MPB [13]; as such reduced insulin action 234	
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on muscle may also exacerbate muscle wasting [3]. In support of this, without 235	
treatment most T1D individuals display dramatic weight loss, while weight loss 236	
and muscle mass can be much improved with insulin therapy [3]. Overall, 237	
T1DM results in an increase in both WBPS and WBPB. Increases in WBPB 238	
are greater than WBPS such that negative net balance occurs, with the 239	
majority of this coming from muscle protein sources [3]. With regard to 240	
feeding, supplementary leucine increased whole-body protein accretion in 241	
T1DM via suppression of protein breakdown [35]. 242	
T2D is primarily characterized by tissue insulin resistance (IR). Initially, 243	
insulin secretion increases, yet over time insulin secretion is inadequate to 244	
overcome IR [3]. T2D is a result of genetic and environmental factors, the risk 245	
being increased with obesity and physical inactivity. T2D is associated with a 246	
greater decline in muscle mass especially with ageing [36]. Nonetheless, 247	
WBPS, WBPB and NB were shown to be comparable between controls and 248	
T2DM patients and with no difference in MPS [37]. Additionally, obese T2D 249	
patients, with a lower percentile of appendicular lean mass, displayed no 250	
difference in fasted MPS [38]. Both of these studies further showed equal 251	
response to feeding as controls, with 20g casein [37] and 10/20g of EAA with 252	
maximal stimulation at 10g [38]. This suggests anabolic resistance is not the 253	
mechanism of muscle loss in T2D. Additionally, while there appears to be no 254	
major differences in protein kinetics, people with T2D maintain higher levels of 255	
insulin; whether this is needed to maintain equivalent WBPB is unclear [3].  256	
 257	
What’s new in organ failure nutritional management? 258	
 259	
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Chronic obstructive pulmonary disease (COPD) is characterized by long-term 260	
airflow limitation (“lung failure”) mainly caused by chronic exposure to 261	
cigarette smoke and air born pollutants [39]. Many COPD patients display 262	
cachexia with underlying hyper-metabolism, inflammation and reduced 263	
appetite [40]. COPD patients in the postabsorptive state have shown both 264	
increased or unchanged whole body protein turnover [6,41], yet the effect on 265	
MPS is unknown. Further, the effect of protein feeding has illustrated equal 266	
anabolic responses to healthy controls, with greater responses when a 267	
mixture of leucine enriched EAA (13g-40% leucine) was used compared to a 268	
mixture of total AA (13g-12% leucine) [42]. Overall, nutritional 269	
supplementation in COPD patients has shown increased body weight, with 270	
the use of EAA supplements showing greatest benefits at increasing fat free 271	
mass (FFM) [39].  272	
Chronic kidney disease (CKD) describes the progressive loss of kidney 273	
function that results in end stage renal disease. This is accompanied by a 274	
progressive loss of muscle mass often referred to as protein energy wasting 275	
(PEW), although it has no obvious distinction from cachexia. Muscle loss is 276	
associated with many metabolic abnormalities in CKD including inflammation, 277	
insulin resistance, decreased nutrient intake and dietary restrictions, with 278	
muscle loss further enhanced by dialysis [43]. Whole body protein kinetics 279	
have been shown to be similar between CKD and healthy subjects, however 280	
in the fasted state specifically mixed MPS was lower [44]. The biggest effect 281	
of CKD on muscle kinetics is that through dialysis; resulting in rapid protein 282	
losses through increases in MPB that may persist for several hours after 283	
treatment [44]. In non-dialysis CKD patients, a protein diet of 0.6-0.8g/kg/day 284	
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has been recommended, as a low protein diet may slow the progression to 285	
renal failure. In CKD patients undergoing dialysis a much higher protein intake 286	
of >1.2g/kg/day is recommended [43], and to try and attenuate protein losses, 287	
many studies have provided intradialysis supplementation. Enteral nutritional 288	
support has previously shown effectiveness at attenuating catabolism [45]. 289	
However recently, CKD patients receiving a meal containing 30g of protein 290	
90-min after the start of each treatment for 6-months did not prevent losses in 291	
lean mass [46]. Furthermore, consumption of either 27g whey protein, soy 292	
protein or placebo 15 minutes prior to the start of dialysis for 6 months had no 293	
effect on lean mass [47]. Similarly consumption of 3g of calcium-HMB per day 294	
for 6-months had no effects on lean body mass [27,48]. However, in both 295	
these studies lean mass remained stable in control and treatment groups. An 296	
additional option is the use of intradialytic parental nutrition, utilizing mixtures 297	
high in amino acids, glucose and lipids. Although showing benefits on nitrogen 298	
balance and body weight, recent studies focusing on muscle outcomes are 299	
limited, with intra-dialytic parenteral nutrition (IDPN) further seen as a short-300	
term nutritional approach [45]. Both enteral and parental intradialytic 301	
supplementations offer a safe means to increase nutritional intake. However 302	
nutritional modulation in CKD should take individual characteristics and 303	
clinical condition into consideration [45]. 304	
 Congestive heart failure (CHF) is impaired ventricular ejection and or 305	
filling capacity caused by structural or functional abnormalities. Accompanying 306	
heart failure is progressive involuntary weight loss, often referred to as cardiac 307	
cachexia [49]. Skeletal muscle loss is always the result of an imbalance 308	
between anabolic and catabolic factors, yet there is a lack of studies looking 309	
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at protein kinetics in heart failure, with only one study demonstrating that 310	
generally whole body protein turnover is unaffected [50]. As such the 311	
presence of anabolic resistance in HF is unknown. Malnutrition is often 312	
present in these patients and so nutritional support is recommended; yet there 313	
are no specific guidelines for protein and energy intake. The use of protein 314	
rich high calorie supplementation, and similarly EAA, have previously shown 315	
benefits in body weight in most patients [51]. 316	
 Finally, acute multiple organ failure through the onset of acute illness 317	
and/or trauma is an often overlooked area of clinical nutrition. The accelerated 318	
loss of muscle in ICU patients (estimated at a striking 1-2%/d; [52]) through 319	
increased MPB and decreased MPS has devastating consequences on 320	
recovery, morbidity and mortality, even following discharge [53]. Due to the 321	
multifaceted causes of critical illness, alongside the extended periods of 322	
bedrest, nutritional management can be complicated. Of the few studies that 323	
have been performed, potential dietary manipulation with the EAA leucine and 324	
in particular its metabolite HMB have shown efficacy, improving nitrogen 325	
balance in trauma ICU patients [52]. Other anti-catabolic drugs and 326	
nutraceuticals (e.g. N-3 fatty acids, metformin) that have been tested in acute 327	
patients are discussed in detail in a recent review for this journal [54], 328	
however large RCT’s are still lacking. Yet it is unlikely that any one nutritional 329	
intervention will be the “magic bullet” for preventing wasting in ICU patients, 330	
and nutritional therapies should be carefully individualized to each patient 331	
dependent on cause of admission. 332	
 333	
Conclusions  334	
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 335	
Many chronic diseases described herein are associated with a significant and 336	
progressive wasting of muscle mass that increases the risk of mortality. There 337	
are common underlying abnormalities e.g. inflammation, hyper-metabolism, 338	
insulin/anabolic resistance - all contributing the irreversible nature of cachexia 339	
to standard nutrition. Despite the trialing of nutritional interventions, there is 340	
considerable inconsistencies and variability among results- assumably due to 341	
the type of disease. Acutely, protein feeding high in EAA content has shown 342	
to be effective at promoting a full anabolic response on the whole body and 343	
muscle level. Fulfilling energy requirements through high calorie/high protein 344	
nutritional approaches is therefore icily to be beneficial in many situations of 345	
disease-induced muscle wasting. However, recommendations should be 346	
specialized, as nutritional requirements and route of administration may vary 347	
considerably across disease state and progression. This review also 348	
highlights areas where lack of clinical progress is being made; including a 349	
number of the topics we cover herein, in addition to those with little-to no new 350	
data not covered e.g. chronic liver disease. 351	
 352	
Key Points 353	
 354	
- Many diseases are accompanied with a significant and progressive 355	
muscle wasting known as cachexia, which is a strong predictor of 356	
mortality. The specific underlying mechanisms to muscle wasting in 357	
disease are incompletely defined, yet many conditions display 358	
inflammation, increased energy expenditure and malnutrition.  359	
 360	
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- Protein loss occurs through an imbalance between protein synthesis 361	
and protein breakdown. Using stable isotope techniques to study 362	
protein kinetics, the mechanism of protein loss can be studied and 363	
effective therapeutics devised.  364	
 365	
- These techniques have revealed altered protein kinetics that favour 366	
catabolism and have identified the presence of anabolic resistance in 367	
many disease states. Currently, protein high in EAA has shown 368	
effectiveness at promoting anabolism. 369	
 370	
- There are considerable inconsistencies among the efficacy of 371	
nutritional interventions in disease induced muscle wasting. Currently 372	
high calorie high protein (EAA) supplementation has shown to be most 373	
effective at attenuating muscle loss. 374	
 375	
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Figure Legend 395	
Figure 1 an overview of disease induced muscle wasting. Cachexia is a 396	
complex syndrome that is associated with many disease states. The 397	
development of muscle wasting with disease is multifactorial, with chronic 398	
disease often resulting in changes in habitual behavior such as malnutrition 399	
and inactivity; along with many adverse effects from drug treatments. These 400	
factors are themselves associated with muscle loss and can exacerbate 401	
negative disease outcomes. The underlying mechanisms of cachexia across 402	
disease states are unclear, although share common characteristics such as 403	
inflammation, increased REE and insulin resistance. Loss of muscle mass 404	
must occur through an overall imbalance between protein synthesis and 405	
protein breakdown. Protein kinetics has shown to be frequently altered, 406	
generally favoring a catabolic environment. Further, impaired anabolic 407	
responses to nutrition are often present likely contributing to the irreversible 408	
nature of cachexia through standard nutritional provision. Many nutritional 409	
interventions have been tried to promote anabolism and attenuate muscle 410	
wasting. Currently protein high in EAA has shown promising affects, yet many 411	
other nutraceutical interventions have shown positive but overall inconsistent 412	
results. REE, resting energy expenditure. PS, protein synthesis. PB, protein 413	
breakdown. EAA, essential amino acids. HMB, β-hydroxy-β-methylbutyrate. 414	
MPS, muscle protein synthesis. 415	
 416	
 417	
 418	
  419	
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* Engelen et al 2015 - Demonstrated an essential amino acid mixture is more 420	
effective at increasing whole body protein synthesis in cancer patients than  421	
that of total amino acids. Further this response was equal to healthy controls 422	
suggesting EAA may be effective in preventing muscle mass loss 423	
* Mikkelsen et al 2015 - First study in rheumatoid arthritis patients to 424	
demonstrate equal responses in muscle protein synthesis and muscle protein 425	
breakdown to whey protein. Indicating that in well-treated rheumatoid arthritis 426	
patients anabolic sensitivity is maintained  427	
* Faber et al 2017 - Showed increased body weight and performance status in 428	
cancer patients using a specially formulated medical food high in EAA, fish oil 429	
and vitamins. Previously, deutz et al 2011 demonstrated this medical food 430	
was effective at increasing acute MPS in cancer patients. Together these 431	
studies show the power of devising anabolic interventions on a acute basis 432	
and implementing them on a long term basis.  433	
* Macdonald et al 2015 - The first study to use D2O to measure long term 434	
musle protein synthesis in patients with upper GI cancer. This reveleaed 435	
increased muscle protein synthesis in cachetic cancer patients, seemingly 436	
contradicting the theory of anabolic resistance in muscle wasting. These 437	
techniques are less invasie to atute tracer studies and will undoubtable 438	
unravel disease induced alterations in kinetics on a long term ‘free living’ 439	
basis  440	
 441	
 442	
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